Abstract:Objective To evaluate the value of transrectal ultrasound-guided systematic prostate biopsy and magnetic resonance imaging(MRI) suspicious targeted biopsy in the biopsy of prostate cancer.Methods A retrospective analysis was performed in 181 patients with suspected prostate cancer underwent transrectal ultrasound-guided prostate biopsy from September 2011 to September 2013 in the Second Affiliated Hospital of Zhejiang University School of Medicine.In all the 181 patients had the transrectal ultrasound-guided systematic biopsy,116 patients with suspicious MRI had two additional targeted biopsies.Prostate cancers were detected in 97 of 181 patients,and the prostatic hyperplasia were detected in 84 patients.The detection rate of transrectal ultrasound-guided systematic prostate biopsy,suspicious MRI targeted biopsy and combined biopsy in prostate cancer were tested by χ2 test.Compared with pathological results,the sensitivity,specificity,accuracy,positive predictive value and negative predictive value of transrectal ultrasound-guided systematic prostate biopsy and suspicious MRI targeted biopsy were calculated and tested by χ2 test.Results Prostate cancer was detected in 97 of 181 patients(53.6%),63(34.8%) was detected by transrectal ultrasound-guided systematic prostate biopsy,and 81(44.8%) was detected by suspicious MRI targeted biopsy.The suspicious MRI targeted biopsy detected more prostate cancers which there had statistical differences compared with transrectal ultrasound-guided systematic prostate biopsy(χ2=34.830,P=0.015).Transrectal ultrasound guided prostate systematic biopsy missed 34 cases of prostate cancer,and suspicious MRI targeted biopsy missed 16 cases,accounting for 35.1%(34/97) and 16.5%(16/97) of prostate cancer.The 181 patients were biopsied a total of 1 896 cores,including transrectal ultrasound guided systematic biopsy 1 448 cores and suspicious MRI targeted biopsy 448 cores.The sensitivity,specifi city,positive predictive value and negative predictive value of suspicious MRI targeted biopsy was 89.8%(280/312),87.4%(1 384/1 584),58.3%(280/480),97.7%(1 384/1 416) compared with the sensitivity of 71.8%(224/312),specifi city of 22.7%(360/1 584),positive predictive value of 15.5%(224/1 448) and negative predictive value of 80.4%(360/448) in transrectal ultrasound-guided systematic prostate biopsy(χ2=14.008,96.037,143.049,170.729,all P < 0.001).Conclusions The detection rate of prostate cancer of suspicious MRI targeted biopsy is higher than transrectal ultrasound-guided systematic prostate biopsy,but can′t replace transrectal ultrasound-guided systematic prostate biopsy.The two methods are complementary to improve the prostate cancer detection rate.

Contrast-enhanced Transrectal Ultrasound Can Reduce Collection of Unnecessary Biopsies when Diagnosing Prostate Cancer and is Predictive of Biochemical Recurrence Following a Radical Prostatectomy in Patients with Localized Prostate Cancer

Significance of contrast-enhanced transrectal ultrasonography for the detection of prostate cancer

The value of transrectal ultrasound-guided systematic prostate biopsy and additional targeted cores from suspicious magnetic resonance imaging in the biopsy of prostate cancer

The value of contrast-enhanced transrectal ultrasound in predicting the nature of prostate diseases and the gleason score of prostate cancer by a subjective blood flow grading scale

PREDICTION OF PROSTATE BIOPSY OUTCOME BY MULTIPARAMETRIC ULTRASOUND IMAGING

Real-time precision targeted prostate biopsy using transrectal ultrasound-magnetic resonance fusion

Contrast-Enhanced Ultrasound-Magnetic Resonance Imaging Radiomics Based Model for Predicting the Biochemical Recurrence of Prostate Cancer: A Feasibility Study

Developing a Follow-Up Strategy for Patients with PSA Ranging from 4 to 10 Ng/ml Via a New Model to Reduce Unnecessary Prostate Biopsies.

Free-hand Transperineal Multiparametric Magnetic Resonance Imaging/transrectal Ultrasound Fusion-Guided Targeted Biopsy for the Diagnosis of Prostate Cancer: a Prospective Study

Assessment of Free-Hand Transperineal Targeted Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion in Chinese Men with Prior Negative Biopsy and Elevated Prostate-Specific Antigen

The Comparative Study on the Application Value of Transperineal Prostate Combined Biopsy and Transrectal Prostate Systematic Biopsy in Diagnosing Prostate Cancer in Patients with Different PSA Zones.

Added Value of Biparametric MRI and TRUS-Guided Systematic Biopsies to Clinical Parameters in Predicting Adverse Pathology in Prostate Cancer

PD53-06 CIRCULATING TUMOR CELLS MAY IMPROVE PSA ABILITY TO PREDICT POSITIVE PROSTATE BIOPSY IN PATIENTS WITH TOTAL SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4–10 NG/ML

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET/CT

Cognitive magnetic resonance imaging-ultrasound fusion transperineal targeted biopsy combined with randomized biopsy in detection of prostate cancer

A Comparative Study of Transrectal Contrast-Enhanced Ultrasound Assisted Prostate Biopsy and System-Ic Prostate Biopsy

[Establishment of a Scoring System for Predicting the Positive Rate of Prostatic Biopsy for Prostate Cancer].

The Predictive Efficacy Of Hypoechoic Lesion In Ultrasound For Prostate Cancer In Chinese People: Five-Year Experience In A Moderated 10-Core Transperineal Prostate Biopsy Procedure

68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study

Clinical Utility of a Novel Urine-Based Gene Fusion TTTY15-USP9Y in Predicting Prostate Biopsy Outcome

The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer